This website does readability filtering of other pages. All styles, scripts, forms and ads are stripped. If you want your website excluded or have other feedback, use this form.

Rapastinel - Allergan - AdisInsight

Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Welcome to AdisInsight

Please enter your official email address Email Address Please enter your official email address Your email address will be used to create a unique number used exclusively to identify you on AdisInsight. Your email address will not be stored or maintained within AdisInsight. Your unique identifier number will be stored in your browser data on your device. This will allow us to know it’s you when you access AdisInsight from your computer, tablet, or phone. To do this you will need to enter your email address the first time to visit AdisInsight from a new device. After that we will recognize you and you will not have to enter your email again unless you have deleted your browser data. We will use your unique identifier number to provide anonymous information to your subscribing organization to allow them to accurately assess the value AdisInsight delivers. For additional information on how we protect your personal information, please refer to our privacy policy .

Rapastinel - Allergan

Next Previous

Search Advanced Search Structure Search Menu Drug Profile

Rapastinel - Allergan

Alternative Names: BV-102; GLYX-13; GLYX-13-peptide; GLYX-13-trifluoroacetate; TPPT-amide; TPPT-amide-trifluoroacetate

Latest Information Update: 02 Aug 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Northwestern University
  • Developer Allergan; Naurex
  • Class Amides; Analgesics; Antidepressants; Neuropsychotherapeutics; Oligopeptides; Small molecules
  • Mechanism of Action NR2B N-Methyl-D-Aspartate receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Bipolar depression; Major depressive disorder; Neuropathic pain

Most Recent Events

  • 29 Jul 2019 Discontinued - Phase-III for Major depressive disorder (Adjunctive treatment, Prevention of relapse) in USA (IV) (NCT03668600)
  • 19 Jul 2019 Discontinued - Phase-III for Major depressive disorder (Monotherapy, Prevention of relapse) in Sweden, Bulgaria, Hungary, Japan, Poland, Slovakia (IV) (NCT03614156)
  • 19 Jul 2019 Naurex withdraws a phase III trial for Major depressive disorder (Monotherapy, Treatment-experienced) in Bulgaria and Sweden, prior to enrolment due to business decision to stop the program (IV) (NCT03855865) (EudraCT2018‐000063‐88)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Login with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at [email protected] so we can help.

Table of Contents

210,000+ scientifically curated records

About Our Content

Other Sites

Help & Contacts



Legal Adis International Ltd. Part of Springer Science+Business Media
© Springer Nature Switzerland AG Not logged in Unaffiliated